Charles River Laboratories to acquire gene therapy CDMO Vigene Biosciences

Charles River Laboratories to acquire gene therapy CDMO Vigene Biosciences

Charles River Laboratories International has signed an all-cash deal worth $292.5 million to acquire Vigene Biosciences, a US-based gene therapy contract development and manufacturing organization (CDMO) that offers viral vector-based gene delivery solutions. Vigene Biosciences also stands to earn up to $57.5 million in contingent additional payments based on its future performance. The acquisition is […]

HemaCare to be acquired by Charles River Laboratories for $380m

HemaCare to be acquired by Charles River Laboratories for $380m

Charles River acquisition of HemaCare : Charles River Laboratories International, an early-stage contract research organization, has agreed to acquire HemaCare for about $380 million in an all-cash deal, as per the latest pharma acquisition news. HemaCare is engaged in the production of human-derived cellular products for the cell therapy market. The company provides critical biomaterials, […]